AUTHORS
Allison Remiker, MD, Sherif M. Badawy, MD, MS, MBA2, Vicky Breakey, MD3, James Bussel, MD4, Rachael Grace, MMSc, MD5, Amanda Grimes, MD6, Elizabeth Gunn, MD, MSPH7, Shipra Kaicker, MD8, Pei-Chi Kao, PHD9, Wendy London, PhD10, Ellis Neufeld, MD, PhD11, Cindy Neunert, MD12, Melissa Rose, DO13, Ruchika Sharma, MD14, Kristin Ammon Shimano, MD15, Robert J. Klaassen I, MD, FRCPC16
AFFILIATIONS
1 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
2 Northwestern University, Chicago, Illinois, United States
3 McMaster University, Hamilton, Canada
4 Weill Cornell University, New York, United States
5 Harvard University, Boston, United States
6 Baylor College, Houston, United States
7 Emory School of Medicine, Atlanta, United States
8 Weill Cornell University, New York, United States
9 Harvard University, Boston, United States
10 Harvard University, Boston, United States
11 St. Jude Research Hospital, Memphis, United States
12 Columbia University, New York, United States
13 Ohio State University, Columbus, United States
14 UT Southwestern, Dallas, United States
15 University of California San Francisco, San Francisco, United States
16 University of Ottawa, Ottawa, Canada
ABSTRACT
Background: The Pediatric ITP Newly diagnosed patients Eltrombopag vs Standard therapy (PINES) trial, was a landmark investigator-initiated, prospective, open label, randomized, multi-center investigator-initiated trial sponsored by the ITP Consortium of North America (ICON) and funded by Novartis (Shimano et al, JAMA 2025). Children receiving eltrombopag saw a significantly higher rate of sustained platelet count improvement in the first 12 weeks in comparison to those on standard therapy (SOC). However, in ITP, disease burden is multifaceted and does not depend on platelet count alone. Important contributors to patient experience include fatigue, bleeding, fear of bleeding, psychological impact, burden of treatment (including adherence challenges and medication-related adverse effects), and social functioning. Given the complexity of disease burden in ITP, we examined the impact of eltrombopag versus SOC on patient-reported outcomes (PROs) in study patients with newly diagnosed ITP.
Methods: Patients were randomized 2:1 to eltrombopag or SOC and were followed for one year, with rescue therapies permitted and second-line therapies allowed after week 12. Secondary outcome analyses included patients who received at least one dose of assigned study treatment. PROs were assessed longitudinally at baseline, 1, 4, 12, and 52 weeks. Health-related quality of life (HR-QoL) was measured using the Kids ITP Tool (KIT) parent proxy, child self-report, and parental impact scores. Global Change Score was assessed using parent proxy-report and child self-report change scales. Fatigue was assessed using child, adolescent, and parent versions of the Hockenberry Fatigue Scale (FS-C, FS-A, FS-P). Higher KIT and Global Change scores are indicative of better well-being, whereas higher Hockenberry Fatigue scores indicate more fatigue.
Results: 78 patients in the eltrombopag arm and 39 in the SOC arm were evaluable for secondary outcomes; 106 patients completed the full 1-year study period.
The change in KIT score from baseline to Week 12 was significantly greater in the eltrombopag group than in the SOC group for the parent proxy (14.3 vs. 6.5 points, respectively; p=0.026) and child self-report (18.9 vs. 9.6 points, respectively; p=0.021). At 1 year, both treatment groups demonstrated sustained improvements from baseline across all KIT domains. Although the improvement in the parent impact report was greater in the SOC arm than in the eltrombopag arm (p=0.039), patients randomized to eltrombopag continued to demonstrate clinically meaningful gains, with mean improvements from baseline in the KIT parent proxy, child self-report, and parent impact scores of 14.3, 14.4, and 27.1 points, respectively, compared with 17.2, 18.2, and 39.6 points in the SOC arm. Global Change Scale scores improved in both treatment groups, with similar trajectories observed for both parent-proxy and child self-report assessments at all time points.
A significantly greater improvement in the FS-P score was observed in the eltrombopag group at Week 12 compared with SOC (p=0.017). However, there were no significant differences between treatment groups identified for FS-C/FS-A at Week 12 or at 1-year.
In all enrolled patients, KIT parent proxy scores correlated with child self-report scores at baseline (r=0.56, p<0.0001) and 1-year (r=0.65, p<0.0001). Higher KIT scores were associated with lower fatigue scores at baseline, including FS-P: r=-0.50, p<0.0001 and FS-C/FS-A: r=-0.43, p=0.0005.
Conclusions: In this interventional trial of pediatric patients with newly diagnosed ITP, patient-reported outcomes improved over time in both treatment arms. HRQoL improvement was significantly greater in the eltrombopag arm at Week 12 as measured by both parent proxy and child self-report. Fatigue measures also showed a greater improvement with eltrombopag compared to SOC at Week 12 based on parent proxy. Global health status improved similarly between groups. Across all patients, higher KIT scores were inversely correlated with fatigue, supporting a strong relationship between improved quality of life and reduced fatigue burden. Overall, eltrombopag improved HRQoL and fatigue during the first 12 weeks, coinciding with improved platelet counts. Long-term differences were limited, likely reflecting similar disease resolution and treatment heterogeneity after Week 12.
DISCLOSURES
Allison Remiker, MD: X4 - Consultancy (Includes expert testimony)